Comprehensive molecular characterization of gastric adenocarcinoma
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Gastric cancer is a leading cause of cancer deaths, but analysis of its molecular and clinical characteristics has been complicated by histological and aetiological heterogeneity. Here we describe a comprehensive molecular evaluation of 295 primary gastric adenocarcinomas as part of The Cancer Genome Atlas (TCGA) project. We propose a molecular classification dividing gastric cancer into four subtypes: tumours positive for Epstein–Barr virus, which display recurrent PIK3CA mutations, extreme DNA hypermethylation, and amplification of JAK2, CD274 (also known as PD-L1) and PDCD1LG2 (also known as PD-L2); microsatellite unstable tumours, which show elevated mutation rates, including mutations of genes encoding targetable oncogenic signalling proteins; genomically stable tumours, which are enriched for the diffuse histological variant and mutations of RHOA or fusions involving RHO-family GTPase-activating proteins; and tumours with chromosomal instability, which show marked aneuploidy and focal amplification of receptor tyrosine kinases. Identification of these subtypes provides a roadmap for patient stratification and trials of targeted therapies. The Cancer Genome Atlas reports on molecular evaluation of 295 primary gastric adenocarcinomas and proposes a new classification of gastric cancers into 4 subtypes, which should help with clinical assessment and trials of targeted therapies. This contribution from The Cancer Genome Atlas (TCGA) project describes the molecular evaluation of 295 primary gastric adenocarcinomas. Based on the results, the authors propose a novel classification separating gastric cancers into four subtypes according to: Epstein–Barr virus positive status, microsatellite instability, chromosomal instability or genomic stability. Given the histologic and etiologic heterogeneity of gastric cancer identification of these subtypes, using a schema that can readily be applied to patient samples should help with patient stratification and trials of targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many of the miRNAs were also reported by a recent systems biology paper from TCGA in 2014 [34].”
From Bioinformatic Interrogation of 5p-arm and 3p-arm Specific miRNA Expression Using TCGA Datasets (2015) · cites this paper as [34]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The fusion of this evidence has prompted TCGA and the Asian Cancer Research Group (ACRG) to propose several molecular classifications [77,78].”
From Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer (2024) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“The TP53/APC double knockout (DKO) organoid line was established in our previous studies by sequentially disrupting TP53 and APC37, two common oncogenic loci in gastric adenocarcinoma38,39, from non-neoplastic human gastric organoids (Fig. S1A).”
From Large-scale CRISPR screening in primary human 3D gastric organoids enables comprehensive dissection of gene-drug interactions (2025) · cites this paper as [38]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Fusobacterium spp. is important in the development and progression of gastrointestinal tumors1,19,34,35”
From RETRACTED ARTICLE: Microbiome analyses of blood and tissues suggest cancer diagnostic approach (2020) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Self-citationLAURÉN, P. (1965) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/apm.1965.64.1.31 · Cited by 6,133
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationWHO Classification of Tumours of the Digestive System
Bosman, F. T. (2010) · Medical Entomology and Zoology · Cited by 5,041
Cell Migration: Integrating Signals from Front to Back
Ridley, A. J., Schwartz, M. A., Burridge, K., Firtel, R. A., Ginsberg, M. H., Borisy, G., Parsons, J. T., & Horwitz, A. R. (2003) · Science · doi:10.1126/science.1092053 · Cited by 4,978
Helicobacter pylori Infection and the Development of Gastric Cancer
Uemura, N., Okamoto, S., Yamamoto, S., Matsumura, N., Yamaguchi, S., Yamakido, M., Taniyama, K., Sasaki, N., & Schlemper, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa001999 · Cited by 4,465
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278
Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,188
Research works printed but not linked: 2
- Ferlay, J. et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide. IARC CancerBase 11, http://globocan.iarc.fr, accessed on January 15, 2014 (2013)
- The Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012) · DOI · Paper page
Cited by
Items 301–400 of 1,024
Derks, S., de Klerk, L. K., Xu, X., Fleitas, T., Liu, K. X., Liu, Y., Dietlein, F., Margolis, C., Chiaravalli, A. M., Da Silva, A. C., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.011 · Cited by 163
Chung, H. C., Bang, Y.-J., S Fuchs, C., Qin, S.-K., Satoh, T., Shitara, K., Tabernero, J., Van Cutsem, E., Alsina, M., Cao, Z. A., et al. (2021) · Future Oncology · doi:10.2217/fon-2020-0737 · Cited by 165
Prognostic and predictive value of a pathomics signature in gastric cancer
Chen, D., Fu, M., Chi, L., Lin, L., Cheng, J., Xue, W., Long, C., Jiang, W., Dong, X., Sui, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34703-w · Cited by 164
Li, Y., Zheng, Y., Huang, J., Nie, R.-C., Wu, Q.-N., Zuo, Z., Yuan, S., Yu, K., Liang, C.-C., Pan, Y.-Q., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-333617 · Cited by 159
“46 Although reports regarding the functions of NKT cells in ICB therapies remain limited, the current studies have linked NKT cells with improved ICB responses.”
Liu, W., Xie, L., He, Y.-H., Wu, Z.-Y., Liu, L.-X., Bai, X.-F., Deng, D.-X., Xu, X.-E., Liao, L.-D., Lin, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25202-5 · Cited by 164
Straub, M., Drecoll, E., Pfarr, N., Weichert, W., Langer, R., Hapfelmeier, A., Götz, C., Wolff, K.-D., Kolk, A., & Specht, K. (2016) · Oncotarget · doi:10.18632/oncotarget.7593 · Cited by 161
IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma
Moon, J. W., Kong, S.-K., Kim, B. S., Kim, H. J., Lim, H., Noh, K., Kim, Y., Choi, J.-W., Lee, J.-H., & Kim, Y.-S. (2017) · Scientific Reports · doi:10.1038/s41598-017-18132-0 · Cited by 162
miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis
Kang, W., Huang, T., Zhou, Y., Zhang, J., Lung, R. W. M., Tong, J. H. M., Chan, A. W. H., Zhang, B., Wong, C. C., Wu, F., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0134-0 · Cited by 162
Wang, R., Song, S., Harada, K., Ghazanfari Amlashi, F., Badgwell, B., Pizzi, M. P., Xu, Y., Zhao, W., Dong, X., Jin, J., et al. (2020) · Gut · doi:10.1136/gutjnl-2018-318070 · Cited by 162
Clinical impact of tumour biology in the management of gastroesophageal cancer
Lordick, F., & Janjigian, Y. Y. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.15 · Cited by 161
A protein and mRNA expression-based classification of gastric cancer
Setia, N., Agoston, A. T., Han, H. S., Mullen, J. T., Duda, D. G., Clark, J. W., Deshpande, V., Mino-Kenudson, M., Srivastava, A., Lennerz, J. K., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.55 · Cited by 162
Sun, K., Xu, R., Ma, F., Yang, N., Li, Y., Sun, X., Jin, P., Kang, W., Jia, L., Xiong, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32627-z · Cited by 184
Inactivation of Capicua drives cancer metastasis
Okimoto, R. A., Breitenbuecher, F., Olivas, V. R., Wu, W., Gini, B., Hofree, M., Asthana, S., Hrustanovic, G., Flanagan, J., Tulpule, A., et al. (2017) · Nature Genetics · doi:10.1038/ng.3728 · Cited by 160
Böger, C., Behrens, H.-M., Krüger, S., & Röcken, C. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1293215 · Cited by 156
Drugging KRAS: Current perspectives and state-of-art review
Parikh, K., Banna, G., Liu, S. V., Friedlaender, A., Desai, A., Subbiah, V., & Addeo, A. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01375-4 · Cited by 164
Systematic identification of genes with a cancer-testis expression pattern in 19 cancer types
Wang, C., Gu, Y., Zhang, K., Xie, K., Zhu, M., Dai, N., Jiang, Y., Guo, X., Liu, M., Dai, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms10499 · Cited by 158
Saito, R., Abe, H., Kunita, A., Yamashita, H., Seto, Y., & Fukayama, M. (2017) · Modern Pathology · doi:10.1038/modpathol.2016.202 · Cited by 158
Yu, K., Chen, B., Aran, D., Charalel, J., Yau, C., Wolf, D. M., van ‘t Veer, L. J., Butte, A. J., Goldstein, T., & Sirota, M. (2019) · Nature Communications · doi:10.1038/s41467-019-11415-2 · Cited by 156
Nguyen, P. H., Giraud, J., Chambonnier, L., Dubus, P. R., Wittkop, L., Belleannée, G., Collet, D., Soubeyran, I., Évrard, S., Rousseau, B., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2157 · Cited by 172
Kim, J. H., Park, C., Kim, K. H., Kim, E. H., Kim, H., Woo, J. K., Seong, J. K., Nam, K. T., Lee, Y. C., & Cho, S. Y. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00251-1 · Cited by 182
Lee, J. H., Chang, K. K., Yoon, C., Tang, L. H., Strong, V. E. M., & Yoon, S. S. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000002040 · Cited by 173
Pellino, A., Brignola, S., Riello, E., Niero, M., Murgioni, S., Guido, M., Nappo, F., Businello, G., Sbaraglia, M., Bergamo, F., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111095 · Cited by 157
“In 2014, The Cancer Genome Atlas (TCGA) research network reported the results of full genomic profiling of 295 primary gastric adenocarcinomas with the identification of four tumor subgroups: microsatellite unstable tumors (22%), Epstein–Barr virus positive (9%), genomically stable tumors (20%) and chromosomally unsta…”
BackgroundBuck, A., Ly, A., Balluff, B., Sun, N., Gorzolka, K., Feuchtinger, A., Janssen, K., Kuppen, P. J. K., van de Velde, C. J., Weirich, G., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4560 · Cited by 166
Kim, S. Y., Park, C., Kim, H., Park, J., Hwang, J., Kim, J., Choi, M. G., Kim, S. H., Kim, K., & Kang, M.-S. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.09.020 · Cited by 157
Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer
Roviello, G., Ravelli, A., Połom, K., Petrioli, R., Marano, L., Marrelli, D., Roviello, F., & Generali, D. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.014 · Cited by 159
Min, A., Im, S., Jang, H., Kim, S., Lee, M., Kim, D. K., Yang, Y., Kim, H. J., Lee, K.-H., Kim, J. W., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0378 · Cited by 171
Exosome-derived noncoding RNAs in gastric cancer: functions and clinical applications
Tang, X., Guo, T., Gao, X.-Y., Wu, X., Xing, X., Ji, J., & Li, Z. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01396-6 · Cited by 172
Mutational signatures of DNA mismatch repair deficiency in C. elegans and human cancers
Meier, B., Volkova, N. V., Hong, Y., Schofield, P., Campbell, P. J., Gerstung, M., & Gartner, A. (2018) · Genome Research · doi:10.1101/gr.226845.117 · Cited by 154
Cho, S. Y., Park, J. W., Liu, Y., Park, Y. S., Kim, J. H., Yang, H. P., Um, H., Ko, W. R., Lee, B. I., Kwon, S. Y., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.05.012 · Cited by 175
Kataoka, K., Miyoshi, H., Sakata, S., Dobashi, A., Couronné, L., Kogure, Y., Sato, Y., Nishida, K., Gion, Y., Shiraishi, Y., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0380-5 · Cited by 166
Shenoy, S. (2019) · Cancer Management and Research · doi:10.2147/cmar.s208818 · Cited by 183
AQP5 enriches for stem cells and cancer origins in the distal stomach
Tan, S. H., Yada, S., Tan, S., Goh, J., Seishima, R., 村上, 和., Oshima, M., Tsuji, T., Phuah, P., Tan, L. T., et al. (2020) · Nature · doi:10.1038/s41586-020-1973-x · Cited by 162
Jeong, H. Y., Ham, I.-H., Lee, S. H., Ryu, D., Son, S.-Y., Han, S.-U., Kim, T.-M., & Hur, H. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0792 · Cited by 176
The New Era of Immunotherapy in Gastric Cancer
Takei, S., Kawazoe, A., & Shitara, K. (2022) · Cancers · doi:10.3390/cancers14041054 · Cited by 176
Sanchez-Vega, F., Hechtman, J. F., Castel, P., Ku, G. Y., Tuvy, Y., Won, H., Fong, C. J., Bouvier, N., Nanjangud, G. J., Soong, J., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0598 · Cited by 150
The Cancer Cell Map Initiative: Defining the Hallmark Networks of Cancer
Krogan, N. J., Lippman, S., Agard, D. A., Ashworth, A., & Ideker, T. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.05.008 · Cited by 149
Early-onset gastric cancer is a distinct disease with worrisome trends and oncogenic features
Bergquist, J. R., Leiting, J. L., Habermann, E. B., Cleary, S. P., Kendrick, M. L., Smoot, R. L., Nagorney, D. M., Truty, M. J., & Grotz, T. E. (2019) · Surgery · doi:10.1016/j.surg.2019.04.036 · Cited by 163
MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma
van Velzen, M. J. M., Derks, S., van Grieken, N. C. T., Mohammad, N. H., & van Laarhoven, H. W. M. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102024 · Cited by 164
Imai, S., Ooki, T., Murata‐Kamiya, N., Komura, D., Tahmina, K., Wu, W., Takahashi‐Kanemitsu, A., Knight, C. T., Kunita, A., Suzuki, N., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.04.006 · Cited by 166
Wang, X., Li, J., Bian, X., Wu, C., Hua, J., Chang, S., Yu, T., Li, H., Li, Y., Hu, S., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012881118 · Cited by 187
Epidemiology of Gastric Cancer
Rugge, M., Fassan, M., & Graham, D. Y. (2015) · Springer eBooks · doi:10.1007/978-3-319-15826-6_2 · Cited by 180
Ma, C., Patel, K., Singhi, A. D., Ren, B., Zhu, B., Shaikh, F. Y., & Sun, W. (2016) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000698 · Cited by 157
DNA Methylation as a Molecular Biomarker in Gastric Cancer
Tahara, T., & Arisawa, T. (2015) · Epigenomics · doi:10.2217/epi.15.4 · Cited by 148
Helicobacter pylori Infection Causes Characteristic DNA Damage Patterns in Human Cells
Koeppel, M., Garcia-Alcalde, F., Glowinski, F., Schlaermann, P., & Meyer, T. F. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.05.030 · Cited by 148
Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity
Ooi, W. F., Xing, M., Xu, C., Yao, X., Ramlee, M. K., Lim, M. C., Cao, F., Lim, K., Babu, D., Poon, L.-F., et al. (2016) · Nature Communications · doi:10.1038/ncomms12983 · Cited by 146
Guo, Y. A., Chang, M. M., Huang, W., Ooi, W. F., Xing, M., Tan, P., & Skanderup, A. J. (2018) · Nature Communications · doi:10.1038/s41467-018-03828-2 · Cited by 148
Immunotherapy for gastric cancer: dilemmas and prospect
Qingfang, Z., Cao, L., Guan, L., Bie, L., Wang, S., Xie, B., Chen, X., Shen, X., & Cao, F.-L. (2018) · Briefings in Functional Genomics · doi:10.1093/bfgp/ely019 · Cited by 159
Pan, H., Pan, J., Li, P., & Gao, J. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109019 · Cited by 167
MicroRNAs in the etiology of colorectal cancer: Pathways and clinical implications
Strubberg, A. M., & Madison, B. B. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.027441 · Cited by 147
Mathiak, M., Warneke, V. S., Behrens, H., Haag, J., Böger, C., Krüger, S., & Röcken, C. (2015) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000264 · Cited by 152
Chen, X.-X., Zhong, Q., Liu, Y., Yan, S.-M., Chen, Z.-H., Jin, S., Xia, T., Li, R., Zhou, A.-J., Su, Z., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00650-0 · Cited by 154
Mishima, S., Kawazoe, A., Nakamura, Y., Sasaki, A., Kotani, D., Kuboki, Y., Bando, H., Kojima, T., Doi, T., Ohtsu, A., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0514-3 · Cited by 152
Ock, C.-Y., Kim, S., Keam, B., Kim, M., Kim, T. M., Kim, J.-H., Jeon, Y. K., Lee, J.-S., Kwon, S. K., Hah, J. H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7431 · Cited by 144
Lazăr, D. C., Avram, M. F., Romosan, I., Cornianu, M., Tăban, S. M., & Goldiș, A. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i32.3583 · Cited by 168
Zhou, Y., Huang, T., Siu, H. L., Wong, C. C., Dong, Y., Wu, F., Zhang, B., Wu, W. K. K., Cheng, A. S. L., Yu, J. Q., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0647-2 · Cited by 150
Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients
Xing, X., Guo, J., Ding, G., Li, B., Dong, B., Feng, Q., Li, S., Zhang, J., Ying, X., Cheng, X., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1356144 · Cited by 145
Catenacci, D. V. T. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2014.09.011 · Cited by 144
Epigenetic impact of infection on carcinogenesis: mechanisms and applications
Hattori, N., & Ushijima, T. (2016) · Genome Medicine · doi:10.1186/s13073-016-0267-2 · Cited by 153
Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine
Nebot-Bral, L., Brandão, D., Verlingue, L., Rouleau, É., Caron, O., Despras, E., Dakdouki, Y. E., Champiat, S., Aoufouchi, S., Leary, A. F., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.026 · Cited by 154
YAP/TAZ Initiates Gastric Tumorigenesis via Upregulation of MYC
Choi, W., Kim, J., Park, J., Lee, D.-H., Hwang, D., Kim, J.-H., Ashktorab, H., Smoot, D., Kim, S.-Y., Choi, C., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3487 · Cited by 143
Jiang, Y., Xie, J., Han, Z., Liu, W., Xi, S., Huang, L., Huang, W., Lin, T., Zhao, L., Hu, Y., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0848 · Cited by 143
From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer
Vrána, D., Matzenauer, M., Neoral, Č., Aujeský, R., Vrba, R., Melichar, B., Rušarová, N., Bartoušková, M., & Jankowski, J. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010013 · Cited by 156
Recent advances in treating oesophageal cancer
Harada, K., Rogers, J. E., Iwatsuki, M., Yamashita, K., Baba, H., & Ajani, J. A. (2020) · F1000Research · doi:10.12688/f1000research.22926.1 · Cited by 153
Claudins and Gastric Cancer: An Overview
HASHIMOTO, I., & Oshima, T. (2022) · Cancers · doi:10.3390/cancers14020290 · Cited by 154
Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer
Shu, Y., Zhang, W., Hou, Q., Zhao, L.-Y., Zhang, S., Zhou, J., Song, X.-H., Zhang, Y., Jiang, D., Chen, X., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04907-0 · Cited by 155
Prognostic value of tumor-infiltrating lymphocytes in Epstein–Barr virus-associated gastric cancer
Kang, B. W., Seo, A. N., Yoon, S. S., Bae, H., Jeon, S. W., Kwon, O. K., Chung, H. Y., Yu, W., Kang, H., & Kim, J. G. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv610 · Cited by 160
Translational genomics of nasopharyngeal cancer
Tsang, C. M., Lui, V. W. Y., Bruce, J. P., Pugh, T. J., & Lo, K. W. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.006 · Cited by 161
Kim, W., Chu, T. H., Nienhüser, H., Jiang, Z., Portillo, A. D., Remotti, H. E., White, R. A., Hayakawa, Y., Tomita, H., Fox, J. G., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.10.036 · Cited by 155
Shui, L., Ren, H., Yang, X., Li, J., Chen, Z., Cheng, Y., Zhu, H., & Shui, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.570465 · Cited by 173
Waldum, H. L., Sagatun, L., & Mjønes, P. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00001 · Cited by 151
Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma
Derks, S., Nason, K. S., Liao, X., Stachler, M. D., Liu, K. X., Liu, J. B., Sicińska, E., Goldberg, M. S., Freeman, G. J., Rodig, S. J., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0046 · Cited by 147
Six Serum-Based miRNAs as Potential Diagnostic Biomarkers for Gastric Cancer
Huang, Z., Zhu, D., Wu, L., He, M., Xin Min, Z. H. O. U., Zhang, L., Zhang, H., Wang, W., Zhu, J., Cheng, W., et al. (2017) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0607 · Cited by 156
DNA methylation aberrancies as a guide for surveillance and treatment of human cancers
Liang, G., & Weisenberger, D. J. (2017) · Epigenetics · doi:10.1080/15592294.2017.1311434 · Cited by 150
Modeling Human Digestive Diseases With CRISPR-Cas9–Modified Organoids
Fujii, M., Clevers, H., & Sato, T. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.11.048 · Cited by 140
Organoid based personalized medicine: from bench to bedside
Li, Y., Tang, P., Cai, S., Peng, J., & Hua, G. (2020) · Cell Regeneration · doi:10.1186/s13619-020-00059-z · Cited by 136
Hartmaier, R. J., Albacker, L. A., Chmielecki, J., Bailey, M., He, J., Goldberg, M. E., Ramkissoon, S., Suh, J., Elvin, J. A., Chiacchia, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2479 · Cited by 138
Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers
Ock, C.-Y., Hwang, J.-E., Keam, B., Kim, S.-B., Shim, J.-J., Jang, H.-J., Park, S., Sohn, B. H., Cha, M., Ajani, J. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01018-0 · Cited by 138
Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric Cancer
Jiang, Z., Liu, Z., Li, M., Chen, C., & Wang, X. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.07.012 · Cited by 119
Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer
Chakrabarti, J., Holokai, L., Syu, L., Steele, N. G., Chang, J., Wang, J., Ahmed, S., Dlugosz, A., & Zavros, Y. (2018) · Oncotarget · doi:10.18632/oncotarget.26473 · Cited by 138
Kim, I.-H., Kang, S. J., Choi, W., Seo, A. N., Eom, B. W., Kang, B., Kim, B. J., Min, B., Tae, C. H., Choi, C. I., et al. (2025) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2025.25.e11 · Cited by 170
RE.GA.IN.: the Real-world Gastritis Initiative–updating the updates
Rugge, M., Genta, R. M., Malfertheiner, P., Dinis-Ribeiro, M. J., El‐Serag, H. B., Graham, D. Y., Kuipers, E. J., Leung, W. K., Park, J. Y., Rokkas, T., et al. (2024) · Gut · doi:10.1136/gutjnl-2023-331164 · Cited by 173
Injury, repair, inflammation and metaplasia in the stomach
Meyer, A. R., & Goldenring, J. R. (2018) · The Journal of Physiology · doi:10.1113/jp275512 · Cited by 151
Mechanisms and Consequences of Cancer Genome Instability: Lessons from Genome Sequencing Studies
Lee, J.-K., Choi, Y.-L., Kwon, M., & Park, P. J. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044446 · Cited by 135
The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines
Riquelme, I., Tapia, Ó., Espinoza, J. A., Leal, P., Buchegger, K., Sandoval, A., Bizama, C., Araya, J. C., Peek, R. M., & Roa, J. C. (2016) · Pathology & Oncology Research · doi:10.1007/s12253-016-0066-5 · Cited by 148
Diagnostic value of a plasma microRNA signature in gastric cancer: a microRNA expression analysis
Zhou, X., Zhu, W., Li, H., Wen, W., Cheng, W., Wang, F., Wu, Y., Qi, L., Fan, Y., Chen, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep11251 · Cited by 135
Barrett, M. T., Anderson, K. S., Lenkiewicz, E., Andreozzi, M., Cunliffe, H. E., Klassen, C. L., Dueck, A. C., McCullough, A. E., Reddy, S. K., Ramanathan, R. K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4494 · Cited by 134
A Pan-Cancer Catalogue of Cancer Driver Protein Interaction Interfaces
Porta-Pardo, E., Garcia-Alonso, L., Hrabe, T., Dopazo, J., & Godzik, A. (2015) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004518 · Cited by 133
Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy
Riquelme, I., Saavedra, K., Espinoza, J. A., Weber, H. L., García, P., Nervi, B., Garrido, M., Corvalán, A. H., Roa, J. C., & Bizama, C. (2015) · Oncotarget · doi:10.18632/oncotarget.4990 · Cited by 151
Kim, J., Fox, C., Peng, S., Pusung, M., Pectasides, E., Matthée, E., Hong, Y. S., Do, I., Jang, J., Thorner, A. R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75200 · Cited by 140
Helicobacter pylori -induced inflammation and epigenetic changes during gastric carcinogenesis
Valenzuela, M., Canales, J., Corvalán, A. H., & Quest, A. F. G. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i45.12742 · Cited by 149
Lee, S., Lee, S., Ouellette, S., Park, W.-Y., Lee, E. A., & Park, P. J. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx193 · Cited by 133
Link, A., & Kupčinskas, J. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i30.3313 · Cited by 142
Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
Shen, X., Zhang, L., Li, J., Li, Y., Wang, Y., & Xu, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01337 · Cited by 139
“TLRs-independent induction of PD-L1 in virus infection was also uncovered (114, 139, 148).”
BackgroundKang, B., Camps, J., Fan, B., Jiang, H., Ibrahim, M. M., Hu, X., Qin, S., Kirchhoff, D., Chiang, D. Y., Wang, S., et al. (2022) · Genome biology · doi:10.1186/s13059-022-02828-2 · Cited by 155
“Molecular profiling of gastric cancers yielded several sub-classes, including Epstein– Barr virus (EBV)-positive, microsatellite instable (MSI), genomically stable (GS), or chromosomal instable (CIN) [4, 5].”
BackgroundInfluentialMamun, T. I., Younus, S., & Rahman, M. H. (2024) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2024.100845 · Cited by 251
Discovery of Drug Synergies in Gastric Cancer Cells Predicted by Logical Modeling
Flobak, Å., Baudot, A., Rémy, É., Thommesen, L., Thieffry, D., Kuiper, M. T. R., & Lægreid, A. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004426 · Cited by 145
The mutational landscape of hepatocellular carcinoma
Lee, J. (2015) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2015.21.3.220 · Cited by 146
Maeda, M., Moro, H., & Ushijima, T. (2016) · Gastric Cancer · doi:10.1007/s10120-016-0650-0 · Cited by 135
Petrelli, F., Berenato, R., Turati, L., Mennitto, A., Steccanella, F., Caporale, M., Dallera, P., de Braud, F., Pezzica, E., Bartolomeo, M. D., et al. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.01.10 · Cited by 155
Fuchs, C. S., Niedzwiecki, D., Mamon, H. J., Tepper, J. E., Ye, X., Swanson, R. S., Enzinger, P. C., Haller, D. G., Dragovich, T., Alberts, S. R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.2130 · Cited by 143
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Venue
- Nature
- Published
- 2014-07-23
- Volume
- 513
- Issue
- 7517
- Pages
- 202-209
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4170219
- OpenAlex
- W2126547130
- Cited by
- 6,498
- References
- 43
- Citations by year
- 2026: 455 · 2025: 481 · 2024: 569 · 2023: 637 · 2022: 620 · 2021: 737 · 2020: 653 · 2019: 554 · 2018: 560 · 2017: 490 · 2016: 398 · 2015: 297 · 2014: 41
- FWCI
- 327.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-sa)
- KUMeL Repository (Keimyung University) (submittedVersion, cc-by-nc-nd)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- National Institutes of Health
- National Human Genome Research Institute (U54HG003067, R01HG007069, U54HG003079, U54HG003273, R01HG005690)
- National Cancer Institute (P30CA16672, K08CA134931, P50CA098258, U24CA143882, P01CA028842, R01CA180006, U24CA143843, U24CA143840, U24CA143858, U24CA126543, U24CA144025, U24CA143866, U24CA143883, U24CA143845, U24CA180951, U24CA143867, U24CA143848, U24CA143799, U24CA143835, K99CA166729, P30CA008748, P30CA016672, P30CA006973)
- Topics
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Keywords
- gastric adenocarcinoma, molecular classification, Epstein-Barr virus, PIK3CA mutation, DNA hypermethylation, PD-L1, PD-L2, microsatellite instability, chromosomal instability, genome stability, RHOA mutations, aneuploidy, targeted therapy, patient stratification
- MeSH terms
- Adenocarcinoma, Herpesvirus 4, Human, Female, Humans, Male, Mutation, Stomach Neoplasms, Genome, Human, Gene Expression Regulation, Neoplastic, Proteome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.